At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SCNX Scienture Holdings, Inc.
Pre-Mkt 06-16 09:21:20 EDT
0.3603
-0.0176
-4.66%
盘前0.3792
+0.0189+5.25%
09:20 EDT
High0.3979Low0.3491Vol493.37K
Open0.3930D1 Closing0.3779Amplitude12.91%
Mkt Cap14.64MTradable Cap12.25MTotal Shares40.63M
T/O182.96KT/O Rate1.45%Tradable Shares33.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Scienture says large national health plan adds REZENOPY naloxone spray to formulary
Reuters  ·  06-09
Scienture says large national health plan adds REZENOPY naloxone spray to formulary
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
GlobeNewswire  ·  06-09
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
Scienture wins US patent for REZENOPY naloxone nasal spray, protection through 2041
Reuters  ·  06-02
Scienture wins US patent for REZENOPY naloxone nasal spray, protection through 2041
Scienture Receives U.S. Patent Covering Rezenopy™ (Naloxone Hcl) Nasal Spray 10 Mg, Strengthening Intellectual Property Protection Through 2041
THOMSON REUTERS  ·  06-02
Scienture Receives U.S. Patent Covering Rezenopy™ (Naloxone Hcl) Nasal Spray 10 Mg, Strengthening Intellectual Property Protection Through 2041
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
GlobeNewswire  ·  06-02
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
BRIEF-Scienture - Eric Sherb Resigns As CFO Effective May 26, 2026
Reuters  ·  05-30
BRIEF-Scienture - Eric Sherb Resigns As CFO Effective May 26, 2026
Scienture - Appoints Narasimhan Mani as Interim CFO Effective May 26, 2026 - SEC Filing
THOMSON REUTERS  ·  05-30
Scienture - Appoints Narasimhan Mani as Interim CFO Effective May 26, 2026 - SEC Filing
Scienture names Narasimhan Mani interim CFO after Eric Sherb resigns
Reuters  ·  05-30
Scienture names Narasimhan Mani interim CFO after Eric Sherb resigns
Scienture Holdings Q1 revenue jumps on Arbli sales, operating expenses steady
Reuters  ·  05-18
Scienture Holdings Q1 revenue jumps on Arbli sales, operating expenses steady
Scienture Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
THOMSON REUTERS  ·  05-18
Scienture Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
Scienture Holdings, Inc Q1 Gross Profit USD 54 Thousand
THOMSON REUTERS  ·  05-18
Scienture Holdings, Inc Q1 Gross Profit USD 54 Thousand
Scienture Holdings, Inc Q1 Operating Expenses USD 3.56 Million
THOMSON REUTERS  ·  05-18
Scienture Holdings, Inc Q1 Operating Expenses USD 3.56 Million
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
GlobeNewswire  ·  05-18
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
Scienture Holdings Q1 EPS $(0.08) Beats $(0.22) Estimate, Sales $56.325K Up From $10.258K YoY
Benzinga  ·  05-16
Scienture Holdings Q1 EPS $(0.08) Beats $(0.22) Estimate, Sales $56.325K Up From $10.258K YoY
Scienture net loss widens 11% to $3.4 million in Q1 FY26
Reuters  ·  05-16
Scienture net loss widens 11% to $3.4 million in Q1 FY26
Scienture Holdings Inc expected to post a loss of 22 cents a share - Earnings Preview
Reuters  ·  05-16
Scienture Holdings Inc expected to post a loss of 22 cents a share - Earnings Preview
Scienture Holdings Inc expected to post a loss of 22 cents a share - Earnings Preview
Reuters  ·  05-09
Scienture Holdings Inc expected to post a loss of 22 cents a share - Earnings Preview
BRIEF-Scienture Secures $11.0 Million In Non-Dilutive Debt Financing To Accelerate Growth Of Approved Product Portfolio And Advancement Of Research And Development Pipeline
Reuters  ·  05-07
BRIEF-Scienture Secures $11.0 Million In Non-Dilutive Debt Financing To Accelerate Growth Of Approved Product Portfolio And Advancement Of Research And Development Pipeline
Scienture secures $11 million non-dilutive debt financing from institutional investor
Reuters  ·  05-07
Scienture secures $11 million non-dilutive debt financing from institutional investor
Scienture Holdings - Enters Definitive Agreement With Summit Biosciences for Exclusive U.S. Rights to Commercialize Rezenopy
THOMSON REUTERS  ·  05-07
Scienture Holdings - Enters Definitive Agreement With Summit Biosciences for Exclusive U.S. Rights to Commercialize Rezenopy

Introduction

Company Name.
Scienture Holdings, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which offers price transparency, purchasing capabilities, and other value-added services; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Lutz, Florida.
Issue price:
--